Michael A Nauck Selected Research

BIM 51077

7/2009

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael A Nauck Research Topics

Disease

105	Type 2 Diabetes Mellitus (MODY) 11/2022 - 03/2002
20	Body Weight (Weight, Body) 02/2022 - 04/2002
15	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 03/2002
13	Weight Loss (Weight Reduction) 01/2021 - 09/2003
12	Myocardial Infarction 01/2021 - 10/2005
9	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/2022 - 08/2015
9	Pancreatitis 01/2020 - 07/2013
9	Weight Gain 09/2017 - 04/2002
7	Stroke (Strokes) 01/2021 - 01/2016
7	Nausea 10/2020 - 06/2005
6	Obesity 01/2022 - 04/2002
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 11/2013
6	Heart Failure 01/2021 - 01/2016
6	Insulin Resistance 01/2021 - 06/2008
5	Hyperglycemia 01/2021 - 12/2004
5	Vomiting 10/2020 - 06/2005
5	Glucose Intolerance 05/2020 - 11/2003
4	Neoplasms (Cancer) 01/2020 - 05/2007
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 07/2013
3	Inflammation (Inflammations) 01/2022 - 03/2004
3	Chronic Pancreatitis 01/2020 - 07/2013
3	Diabetes Mellitus 01/2020 - 09/2009
3	Acute Coronary Syndrome 01/2018 - 07/2002
2	Chronic Renal Insufficiency 01/2022 - 03/2004
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 08/2015
2	COVID-19 01/2021 - 12/2020
2	Peripheral Arterial Disease 01/2019 - 01/2018
2	Injection Site Reaction 02/2016 - 04/2014
2	Critical Illness (Critically Ill) 01/2015 - 03/2004
2	Urinary Tract Infections (Urinary Tract Infection) 01/2014 - 09/2011
2	Infections 01/2014 - 09/2011
1	Albuminuria 01/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Fatty Liver 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Vascular Diseases (Vascular Disease) 01/2021
1	Diabetes Complications 01/2021
1	Constipation 10/2020
1	Diarrhea 10/2020
1	Dyspepsia (Indigestion) 10/2020
1	Gastroesophageal Reflux (GERD) 01/2020
1	Amyloid Plaque 01/2020

Drug/Important Bio-Agent (IBA)

60	Glucose (Dextrose)FDA LinkGeneric 02/2022 - 03/2002
52	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 03/2002
38	Insulin (Novolin)FDA Link 03/2022 - 05/2003
31	IncretinsIBA 01/2022 - 03/2004
29	Liraglutide FDA Link 01/2022 - 06/2005
25	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 05/2006
15	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 07/2009
14	Hormones (Hormone)IBA 01/2021 - 03/2002
13	Glucagon-Like Peptide-1 ReceptorIBA 01/2021 - 10/2014
11	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2020 - 11/2006
10	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 01/2022 - 01/2003
10	Sitagliptin Phosphate (Januvia)FDA Link 12/2020 - 11/2006
10	Peptides (Polypeptides)IBA 01/2019 - 04/2004
9	semaglutideIBA 01/2022 - 02/2016
9	Exenatide (Byetta)FDA Link 01/2021 - 06/2005
8	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021 - 06/2008
7	Glucagon (Glukagon)FDA Link 01/2021 - 03/2002
6	Blood Glucose (Blood Sugar)IBA 01/2015 - 03/2004
5	dulaglutideIBA 10/2020 - 01/2017
5	lixisenatideIBA 01/2020 - 01/2017
5	Insulin Glargine (Lantus)FDA Link 01/2020 - 07/2010
5	Pharmaceutical PreparationsIBA 01/2018 - 01/2006
5	VildagliptinIBA 11/2016 - 11/2006
4	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 09/2011
4	tirzepatideIBA 01/2021 - 11/2018
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2020 - 03/2004
4	rGLP-1 proteinIBA 12/2019 - 04/2014
4	C-PeptideIBA 02/2016 - 05/2003
4	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2016 - 03/2004
3	Sodium-Glucose Transport ProteinsIBA 01/2022 - 09/2011
3	omega-Chloroacetophenone (Mace)IBA 01/2020 - 01/2019
3	Amylases FDA Link 01/2017 - 11/2003
2	AcidsIBA 11/2022 - 01/2020
2	CarbohydratesIBA 02/2022 - 01/2017
2	SodiumIBA 01/2021 - 01/2021
2	octanoic acid (caprylic acid)IBA 01/2021 - 06/2003
2	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 01/2020 - 11/2016
2	Glucagon-Like Peptides (Enteroglucagon)IBA 01/2020 - 01/2006
2	EnzymesIBA 01/2017 - 07/2010
2	Lipase (Acid Lipase)FDA Link 01/2017 - 11/2014
2	Therapeutic UsesIBA 01/2016 - 07/2002
2	taspoglutideIBA 09/2013 - 07/2009
2	ProinsulinIBA 12/2012 - 10/2010
1	Triglycerides (Triacylglycerol)IBA 01/2022
1	LinagliptinIBA 01/2022
1	Biological ProductsIBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	LDL CholesterolIBA 01/2020
1	CreatinineIBA 01/2020
1	AlbuminsIBA 01/2020

Therapy/Procedure

33	Therapeutics 01/2022 - 04/2004
5	Glycemic Control 02/2016 - 06/2008
4	Injections 01/2021 - 06/2005
3	Aftercare (After-Treatment) 01/2022 - 04/2011
3	Intravenous Infusions 01/2017 - 12/2003
2	Bariatric Surgery 01/2018 - 01/2016
2	Drug Therapy (Chemotherapy) 05/2007 - 04/2002